The settlement resolves allegations that, from 2002 through 2005, Otsuka knowingly promoted the sale and use of Abilify for pediatric use and to treat dementia-related psychosis, although at the time, the FDA had not approved the drug for use in geriatric patients, teenagers or children. Last November, the FDA did approve Abilify for teenagers.
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Comments